Skip to main content
Premium Trial:

Request an Annual Quote

There's Nothing Quite Like Industry Politics (Unless You're in Academia)

GSK is cutting staff, and a lot of it, reports Derek Lowe at In the Pipeline. "I'm hearing that the smallest cuts are around 40% of the entire research staff at the various sites,"  he writes. For those who have never been through a layoff, or are new to industry, Lowe wonders how much the "grass is greener" mentality will play into departing scientists' ideas of why they were let go. Some scientists make a career decision to leave before the ship sinks, while others, says Lowe, leave before management figures out they never should have been there in the first place. "Many GSK scientists are (understandably) feeling as if they're being ditched in favor of a bunch of people whose main advantage is that upper management isn’t so familiar with them yet."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.